YAP/TAZ Signaling and Resistance to Cancer Therapy

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

5-Fluorouracil: mechanisms of action and clinical strategies

Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · see citing works

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C. A., Gambacorti-Passerini, C. B., Niederwieser, D. W., Resta, D. J., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,005 · see citing works

The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP

Huang, J., Wu, S., Barrera, J. A., Matthews, K. A., & Pan, D. (2005) · Cell · doi:10.1016/j.cell.2005.06.007 · Cited by 1,870 · see citing works

A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors

Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651 · see citing works

Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling

Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628 · see citing works

Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP

Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes &amp; Development · doi:10.1101/gad.192856.112 · Cited by 1,452 · see citing works

The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells

Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,261 · see citing works

Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth

Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., & Piccolo, S. (2015) · Nature Cell Biology · doi:10.1038/ncb3216 · Cited by 1,219 · see citing works

hippo Encodes a Ste-20 Family Protein Kinase that Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with salvador and warts

Wu, S., Huang, J., Dong, J., & Pan, D. (2003) · Cell · doi:10.1016/s0092-8674(03)00549-x · Cited by 1,101 · see citing works

The quest to overcome resistance to EGFR-targeted therapies in cancer

Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,055 · see citing works

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,045 · see citing works

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,040 · see citing works

TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation

Hong, J.-H., Hwang, E. S., McManus, M. T., Amsterdam, A., Tian, Y., Kalmukova, R., Mueller, E., Benjamin, T., Spiegelman, B. M., Sharp, P. A., et al. (2005) · Science · doi:10.1126/science.1110955 · Cited by 1,009 · see citing works

The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis

Harvey, K. F., Pfleger, C. M., & Hariharan, I. K. (2003) · Cell · doi:10.1016/s0092-8674(03)00557-9 · Cited by 983 · see citing works

The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation.

Justice, R. W., Zilian, O., Woods, D. F., Noll, M., & Bryant, P. J. (1995) · Genes &amp; Development · doi:10.1101/gad.9.5.534 · Cited by 977 · see citing works

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · see citing works

Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 amplicon

Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C., Brugge, J. S., & Haber, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605579103 · Cited by 885 · see citing works

salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines

Tapon, N., Harvey, K. F., Bell, D. W., Wahrer, D. C. R., Schiripo, T. A., Haber, D. A., & Hariharan, I. K. (2002) · Cell · doi:10.1016/s0092-8674(02)00824-3 · Cited by 858 · see citing works

The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells

Lindau, D., Gielen, P. R., Kroesen, M., Wesseling, P., & Adema, G. J. (2012) · Immunology · doi:10.1111/imm.12036 · Cited by 817 · see citing works

The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals

Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.06.015 · Cited by 804 · see citing works

Metabolic control of YAP and TAZ by the mevalonate pathway

Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 779 · see citing works

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · see citing works

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Rowinsky, E. K. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 724 · see citing works

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 2× · see citing works

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

Feng, X., Degese, M. S., Iglesias‐Bartolomé, R., Vaque, J. P., Molinolo, A., Rodrigues, M. W., Zaidi, M. R., Ksander, B. R., Merlino, G. T., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 559 · see citing works

Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway

Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D.-S., & Guan, K.-L. (2015) · Nature Cell Biology · doi:10.1038/ncb3111 · Cited by 557 · see citing works

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

Wang, G., Lü, X., Dey, P., Deng, P., Wu, C.-C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 556 · see citing works

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works

AMPK modulates Hippo pathway activity to regulate energy homeostasis

Wang, W., Xiao, Z.-D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., & Chen, J. (2015) · Nature Cell Biology · doi:10.1038/ncb3113 · Cited by 549 · see citing works

MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway

Meng, Z., Moroishi, T., Mottier, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H. W., Mo, J., Lü, W., Lu, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9357 · Cited by 524 · see citing works

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Perez, E. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0366 · Cited by 523 · see citing works

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508 · see citing works

Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2

Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., & Pan, D. (2013) · Cell · doi:10.1016/j.cell.2013.08.025 · Cited by 506 · see citing works

Acquired resistance to immunotherapy and future challenges

Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 463 · see citing works

Pancreatic Cancer Chemoresistance to Gemcitabine

Amrutkar, M., & Gladhaug, I. P. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 450 · see citing works

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 435 · see citing works

Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood

Joung, J., Engreitz, J., Konermann, S., Abudayyeh, O. O., Verdine, V. K., Aguet, F., Gootenberg, J. S., Sanjana, N. E., Wright, J. B., Fulco, C. P., et al. (2017) · Nature · doi:10.1038/nature23451 · Cited by 422 · see citing works

Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets<i>Cyr61</i>and<i>CTGF</i>

Lai, D., Ho, K. C., Hao, Y., & Yang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2711 · Cited by 416 · see citing works

YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers

Stein, C., Bardet, A. F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schübeler, D., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005465 · Cited by 414 · see citing works

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414 · see citing works

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400 · see citing works

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

Bartucci, M., Dattilo, R., Moriconi, C., Pagliuca, A., Mottolese, M., Federici, G., Benedetto, A. D., Todaro, M., Stassi, G., Sperati, F., et al. (2014) · Oncogene · doi:10.1038/onc.2014.5 · Cited by 353 · see citing works

Yap1 Phosphorylation by c-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage

Levy, D., Adamovich, Y., Reuven, N. B., & Shaul, Y. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.022 · Cited by 348 · see citing works

Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe

Castedo, M., Perfettini, J.-L., Roumier, T., & Kroemer, G. (2002) · Cell Death &amp; Differentiation · doi:10.1038/sj.cdd.4401130 · Cited by 345 · see citing works

Giving AXL the axe: targeting AXL in human malignancy

Gay, C. M., Balaji, K., & Byers, L. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.428 · Cited by 337 · see citing works

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324 · see citing works

Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway

Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313 · see citing works

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

Cottini, F., Hideshima, T., Xu, C., Sattler, M., Dori, M., Agnelli, L., ten Hacken, E., Bertilaccio, M. T. S., Antonini, E., Neri, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3562 · Cited by 310 · see citing works

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

Zanconato, F., Battilana, G., Forcato, M., Filippi, L., Azzolin, L., Manfrin, A., Quaranta, E. G., Biagio, D. D., Sigismondo, G., Guzzardo, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0158-8 · Cited by 309 · see citing works

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

van Rensburg, H. J. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 307 · see citing works

ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types

Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M. P., & Brabletz, T. (2016) · Nature Communications · doi:10.1038/ncomms10498 · Cited by 305 · see citing works

Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase

Kantarjian, H. M., Cortes, J. E., O'Brien, S. M., Giles, F. J., Albitar, M. X., Rios, M. B., Shan, J., Faderl, S. H., Garcia‐Manero, G., Thomas, D. A., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3547 · Cited by 295 · see citing works

YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers

Galli, G. G., Carrara, M., Yuan, W.-C., Valdes-Quezada, C., Gurung, B., Pepe-Mooney, B., Zhang, T., Geeven, G., Gray, N. S., de Laat, W., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.001 · Cited by 290 · see citing works

Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ

Kim, M., Kim, T., Johnson, R. L., & Lim, D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.015 · Cited by 285 · see citing works

Single tumor-initiating cells evade immune clearance by recruiting type II macrophagesPreprint

Guo, X., Zhao, Y., Yan, H., Yang, Y., Shen, S., Dai, X., Ji, X., Ji, F., Gong, X., Li, L., et al. (2017) · Genes & Development · doi:10.1101/gad.294348.116 · Cited by 283 · see citing works

Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation

Peng, C., Zhu, Y., Zhang, W., Liao, Q., Chen, Y., Zhao, X., Guo, Q., Shen, P., Zhen, B., Qian, X., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.10.010 · Cited by 283 · see citing works

The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

Song, S., Honjo, S., Jin, J., Chang, S.-S., Scott, A. W., Chen, Q., Kalhor, N., Correa, A. M., Hofstetter, W. L., Albarracin, C. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2191 · Cited by 274 · see citing works

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling

Noland, C. L., Gierke, S., Schnier, P. D., Murray, J. M., Sandoval, W. N., Sagolla, M. S., Dey, A., Hannoush, R. N., Fairbrother, W. J., & Cunningham, C. N. (2015) · Structure · doi:10.1016/j.str.2015.11.005 · Cited by 268 · see citing works

Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

Kim, M. H., Kim, J., Hong, H., Lee, J. J.-K., Lee, J., Jung, E., & Kim, J. (2015) · The EMBO Journal · doi:10.15252/embj.201592081 · Cited by 259 · see citing works

Resistant mechanisms to BRAF inhibitors in melanoma

Manzano, J. L., Layos, L., Bugés, C., Gil, M. D. L. L., Vilà, L., Martinez‐Balibrea, E., & Martínez‐Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 256 · see citing works

Targeted therapy in cancer

Tsimberidou, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 255 · see citing works

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Sos, M. L., Fischer, S., Ullrich, R. T., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J. M., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 255 · see citing works

Clinical trials for BET inhibitors run ahead of the science

Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247 · see citing works

YAP Nuclear Localization in the Absence of Cell-Cell Contact Is Mediated by a Filamentous Actin-dependent, Myosin II- and Phospho-YAP-independent Pathway during Extracellular Matrix Mechanosensing

Das, A., Fischer, R. S., Pan, D., & Waterman, C. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708313 · Cited by 246 · see citing works

YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma

Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241 · see citing works

The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis

Zhang, X., Qiao, Y., Wu, Q., Chen, Y., Zou, S., Liu, X., Zhu, G., Zhao, Y., Chen, Y., Yu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15280 · Cited by 234 · see citing works

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P., Timms, K. M., Abkevich, V., Schackmann, E. A., Wapnir, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0085 · Cited by 233 · see citing works

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma

Xu, M. Z., Chan, S. W., Liu, A., Wong, K. F., Fan, S., Chen, J., Poon, R. T. P., Zender, L., Lowe, S. W., Hong, W., et al. (2010) · Oncogene · doi:10.1038/onc.2010.504 · Cited by 228 · see citing works

Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation

Tang, Y., Feinberg, T. Y., Keller, E. T., Li, X.-Y., & Weiss, S. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3394 · Cited by 212 · see citing works

STRIPAK Complexes: structure, biological function, and involvement in human diseases

Hwang, J., & Pallas, D. (2013) · International Journal of Biochemistry and Cell Biology · doi:10.1016/j.biocel.2013.11.021 · Cited by 210 · see citing works

Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma

Murakami, S., Shahbazian, D., Surana, R., Zhang, W.-Y., Chen, H., Graham, G., White, S. M., Weiner, L., & Yi, C.-L. (2016) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 197 · see citing works

Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-κB-dependent XIAP Up-Regulation

Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402305200 · Cited by 194 · see citing works

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis

Fang, L., Teng, H., Wang, Y., Liao, G., Weng, L., Li, Y., Wang, X., Jin, J., Jiao, C., Chen, L., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.002 · Cited by 185 · see citing works

Targeting Cancer Cells with BET Bromodomain InhibitorsPreprint

Xu, Y., & Vakoc, C. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026674 · Cited by 183 · see citing works

Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers

Oku, Y., Nishiya, N., Shito, T., Yamamoto, R., Yamamoto, Y., Oyama, C., & Uehara, Y. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.06.007 · Cited by 180 · see citing works

αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway

Li, P., Silvis, M. R., Honaker, Y., Lien, W.-H., Arron, S. T., & Vasioukhin, V. (2016) · Genes &amp; Development · doi:10.1101/gad.274951.115 · Cited by 180 · see citing works

Promising molecular mechanisms responsible for gemcitabine resistance in cancer

Jia, Y., & Xie, J. (2015) · Genes &amp; Diseases · doi:10.1016/j.gendis.2015.07.003 · Cited by 170 · see citing works

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 170 · see citing works

Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma

Lee, B. S., Park, D. I., Lee, D. H., Lee, J. E., Yeo, M., Park, Y., Lim, D., Choi, W., Lee, D. H., Yoo, G., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.007 · Cited by 166 · see citing works

Palmitic acid dysregulates the Hippo–YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS–STING–IRF3 signaling mechanism

Yuan, L., Mao, Y. J., Luo, W., Wu, W., Xu, H. Y., Wang, X. L., & Shen, Y. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.804005 · Cited by 161 · see citing works

Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma

Kim, W., Khan, S. K., Liu, Y., Xu, R., Park, O., He, Y., Cha, B., Gao, B., & Yang, Y. (2017) · Gut · doi:10.1136/gutjnl-2017-314061 · Cited by 160 · see citing works

The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment

Skibinski, A., Breindel, J. L., Prat, A., Galván, P., Smith, E., Rolfs, A., Gupta, P. B., LaBaer, J., & Kuperwasser, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.038 · Cited by 159 · see citing works

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors

Lin, C., Pelissier, F. A., Zhang, H., Lakins, J. N., Weaver, V. M., Park, C., & LaBarge, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-07-0456 · Cited by 158 · see citing works

A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway

Menendez, J. A., Vellon, L., Mehmi, I., Teng, P. K., Griggs, D. W., & Lupu, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208238 · Cited by 154 · see citing works

SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma

Mao, B., Hu, F., Cheng, J., Wang, P., Xu, M., Yuan, F., Meng, S., Wang, Y., Yuan, Z., & Bi, W. (2013) · Oncogene · doi:10.1038/onc.2013.88 · Cited by 149 · see citing works

Genome-wide Association of Yorkie with Chromatin and Chromatin-Remodeling Complexes

Oh, H., Slattery, M., Ma, L., Crofts, A., White, K. P., Mann, R. S., & Irvine, K. D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.008 · Cited by 145 · see citing works

Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin

Donohue, E., Tovey, A. N., Vogl, A. W., Arns, S., Sternberg, E. D., Young, R. N., & Roberge, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.139915 · Cited by 138 · see citing works

SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK

Bae, S. J., Ni, L., Osinski, A., Tomchick, D. R., Brautigam, C. A., & Luo, X. (2017) · eLife · doi:10.7554/elife.30278 · Cited by 132 · see citing works

The effect of statins on cancer cells—review

Matusewicz, L., Meissner, J. M., Toporkiewicz, M., & Sikorski, A. F. (2015) · Tumor Biology · doi:10.1007/s13277-015-3551-7 · Cited by 131 · see citing works

YAP regulates PD-L1 expression in human NSCLC cells

Miao, J., Hsu, P., Yang, Y., Xu, Z., Dai, Y., Wang, Y., Chan, G., Huang, Z., Hu, B., Li, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23051 · Cited by 130 · see citing works

Role of Hippo signaling in regulating immunity

Hong, L., Li, X., Zhou, D., Geng, J., & Chen, L. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0007-1 · Cited by 127 · see citing works

CDK1 Phosphorylation of YAP Promotes Mitotic Defects and Cell Motility and Is Essential for Neoplastic Transformation

Yang, S., Zhang, L., Liu, M., Chong, R., Ding, S., Chen, Y., & Dong, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2049 · Cited by 126 · see citing works

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

Ciamporcero, E. S., Shen, H., Ramakrishnan, S., Ku, S., Chintala, S., Shen, L., Adelaiye-Ogala, R. M., Miles, K. M., Ullio, C., Pizzimenti, S., et al. (2015) · Oncogene · doi:10.1038/onc.2015.219 · Cited by 125 · see citing works

EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy

Xia, H., Dai, X., Yu, H., Zhou, S., Fan, Z., Wei, G., Tang, Q., Gong, Q., & Bi, F. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0302-x · Cited by 124 · see citing works

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Oppermann, S., Ylanko, J., Shi, Y., Hariharan, S., Oakes, C. C., Brauer, P. M., Zúñiga‐Pflücker, J. C., Leber, B. F., Spaner, D., & Andrews, D. W. (2016) · Blood · doi:10.1182/blood-2015-12-687814 · Cited by 122 · see citing works

Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance

Lee, J. E., Park, H. S., Lee, D., Yoo, G., Kim, T., Jeon, H., Yeo, M., Lee, C. S., Moon, J. Y., Jung, S. S., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.089 · Cited by 119 · see citing works

YAP promotes erlotinib resistance in human non-small cell lung cancer cells

Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 119 · see citing works

Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth

Cox, A. G., Tsomides, A., Yimlamai, D., Hwang, K. L., Miesfeld, J. B., Galli, G. G., Fowl, B. H., Fort, M. W., Kimberly, Y., Sullivan, M. R., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100294 · Cited by 116 · see citing works

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma

Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 110 · see citing works

Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells

Dasari, V. R., Mazack, V., Feng, W., Nash, J. D., Carey, D. J., & Gogoi, R. P. (2017) · Oncotarget · doi:10.18632/oncotarget.15614 · Cited by 108 · see citing works

Down-regulation of Mammalian Sterile 20–Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer Cells

Ren, A., Yan, G., You, B., & Sun, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6248 · Cited by 106 · see citing works

Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p

Gao, Z., Wang, J., Chen, D., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.157 · Cited by 102 · see citing works

Targeting Transcriptional Enhanced Associate Domains (TEADs)

Gibault, F., Sturbaut, M., Bailly, F., Melnyk, P., & Cotelle, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00879 · Cited by 102 · see citing works

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 101 · see citing works

Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway

Chen, M., Wang, M., Xu, S., Guo, X., & Jiang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6298 · Cited by 100 · see citing works

A Novel Acetylation Cycle of Transcription Co-activator Yes-associated Protein That Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating Agents

Hata, S., Hirayama, J., Kajiho, H., Nakagawa, K., Hata, Y., Katada, T., Furutani‐Seiki, M., & Nishina, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334714 · Cited by 95 · see citing works

YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway

Zhao, Y., Khanal, P., Savage, P. B., She, Y., Cyr, T. D., & Yang, X. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2712 · Cited by 95 · see citing works

Hippo pathway mediates resistance to cytotoxic drugs

Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91 · see citing works

Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer

Ciamporcero, E. S., Daga, M., Pizzimenti, S., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.005 · Cited by 91 · see citing works

Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1

Wang, M.-Y., Chen, P., Prakash, E., Hsu, H.-C., Huang, H., Lin, M., Chang, K., & Kuo, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2524 · Cited by 90 · see citing works

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

Nakayama, S., Torikoshi, Y., Takahashi, T., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2231 · Cited by 89 · see citing works

TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells

Elster, D., Tollot, M., Schlegelmilch, K., Ori‬‬, A., Rosenwald, A., Sahai, E. A., & von Eyß, B. (2018) · Nature Communications · doi:10.1038/s41467-018-05370-7 · Cited by 85 · see citing works

Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma

Huo, X., Zhang, Q., Liu, A. M., Tang, C., Gong, Y., Bian, J., Luk, J. M., Xu, Z., & Chen, J. (2012) · Oncology Reports · doi:10.3892/or.2012.2176 · Cited by 84 · see citing works

miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression

Chen, M., Wu, L., Tu, J., Zhao, Z., Fan, X., Mao, J., Weng, Q., Wu, X., Huang, L., Xu, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.010 · Cited by 83 · see citing works

The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma

Yoshikawa, K., Noguchi, K., Nakano, Y., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2948 · Cited by 79 · see citing works

YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells

Xia, Y., Zhang, Y., Yu, C. Y., Chang, T., & Fan, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109575 · Cited by 78 · see citing works

Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling

Wang, H., Lu, B., Cabrera, J. C., Zhang, Y., Yang, Z., McAllister, G., Lindeman, A., Reece-Hoyes, J. S., Tallarico, J. A., Russ, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.722967 · Cited by 78 · see citing works

Yorkie Promotes Transcription by Recruiting a Histone Methyltransferase Complex

Oh, H., Slattery, M. G., Ma, L., White, K. P., Mann, R. S., & Irvine, K. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.017 · Cited by 77 · see citing works

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75 · see citing works

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74 · see citing works

Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells

Dai, X.-Y., Zhuang, L., Wang, D., Zhou, T., Chang, L.-L., Gai, R., Zhu, D., Yang, B., Zhu, H., & He, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.6903 · Cited by 73 · see citing works

Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ

Mesrouze, Y., Meyerhofer, M., Bokhovchuk, F. M., Fontana, P., Zimmermann, C., Martin, T., Delaunay, C., Izaac, A., Kallen, J. A., Schmelzle, T., et al. (2017) · Protein Science · doi:10.1002/pro.3312 · Cited by 70 · see citing works

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance

Wang, D., Wu, Y., Huang, J., Wang, W., Xu, M., Jia, J., Han, G., Mao, B., & Bi, W. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0109-z · Cited by 67 · see citing works

ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP

Muranen, T. E., Selfors, L. M., Hwang, J., Gallegos, L. L., Coloff, J. L., Thoreen, C. C., Kang, S. A. W., Sabatini, D. M., Mills, G. B., & Brugge, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0155 · Cited by 66 · see citing works

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

McGowan, M., Kleinberg, L., Halvorsen, A. R., Helland, Å., & Brustugun, O. T. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.136 · Cited by 65 · see citing works

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer

Zhao, X., Wang, X., Fang, L., Lan, C., Zheng, X., Wang, Y., Zhang, Y., Han, X., Liu, S., Cheng, K., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.015 · Cited by 63 · see citing works

Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells

Zhou, T., Zhuang, L., Hu, Y. W., Zhou, Y., Lin, W., Wang, D., Wan, Z.-Q., Chang, L.-L., Chen, Y., Ying, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30483 · Cited by 62 · see citing works

Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme

Yin, D., Chen, W., O’Kelly, J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25257 · Cited by 59 · see citing works

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

Lee, T., Tseng, Y.-C., Nguyễn, P. A., Li, Y., Ho, C., & Wu, C.-W. (2018) · Scientific Reports · doi:10.1038/s41598-017-18527-z · Cited by 59 · see citing works

TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells

Tian, T., Li, A., Lu, H., Luo, R., Zhang, M., & Li, Z. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.115 · Cited by 58 · see citing works

YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells

Wei, Z., Xiao, L., Xiao-yan, S., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102837 · Cited by 58 · see citing works

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma

Hsu, P., Miao, J., Wang, Y., Zhang, W., Yang, Y., Wang, C., Yang, C., Huang, Z., You, J., Xu, Z., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13593 · Cited by 58 · see citing works

YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells

Dai, Y., Liu, S., Zhang, W., Yang, Y., Hang, P., Wang, H., Cheng, L., Hsu, P., Wang, Y.-C., Xu, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13686 · Cited by 56 · see citing works

Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression

Ma, K., Xu, Q., Wang, S., Zhang, W., Liu, M., Liang, S., Zhu, H., & Xu, N. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.045 · Cited by 55 · see citing works

AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer

Bi, L.-H., Ma, F., Tian, R. L., Zhou, Y., LAN, W.-G., Song, Q., & Cheng, X. (2017) · Gene · doi:10.1016/j.gene.2017.11.017 · Cited by 55 · see citing works

Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.

Jeong, W., Kim, S.-B., Sohn, B. H., et al. (2014) · PubMed · Cited by 54 · see citing works

miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway

Xu, M., Xiao, J., Chen, M., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4252 · Cited by 54 · see citing works

Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling

Zeng, H., Yang, Z., Xu, N., Liu, B., Fu, Z., Lian, C., & Guo, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.248 · Cited by 53 · see citing works

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

Xu, W., Wei, Y., Wu, S., Wang, Y., Wang, Z., Sun, Y., Cheng, S. Y., & Wu, J. (2015) · Cell & Bioscience · doi:10.1186/2045-3701-5-7 · Cited by 52 · see citing works

Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer

Song, R., Gu, D., Zhang, L., Zhang, X., Yu, B., Liu, B., & Xie, J. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22883 · Cited by 51 · see citing works

Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway

Que, K., Tong, Y., Que, G., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6041 · Cited by 50 · see citing works

Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ

Zhan, T., Huang, X., Xia, T., Chen, X., Ding, Y., Luo, H., & Zhang, Y. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.002 · Cited by 50 · see citing works

DNA Methylation As a Clinical Marker in Oncology

Issa, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1016 · Cited by 49 · see citing works

Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP

Tian, Y., Tang, B., Wang, C., Sun, D., Zhang, R., Luo, N., Zhao, H., Liang, R., Gao, Z., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.10079 · Cited by 49 · see citing works

PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway

Fujimoto, D., Ueda, Y., Hirono, Y., Goi, T., & Yamaguchi, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5858 · Cited by 48 · see citing works

TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC

Song, Y., Kim, J.-S., Choi, E. K., Kim, J., Kim, K. M., & Seo, H. R. (2017) · Oncotarget · doi:10.18632/oncotarget.15521 · Cited by 45 · see citing works

Panobinostat sensitizes KRAS‐mutant non‐small‐cell lung cancer to gefitinib by targeting TAZ

Lee, W., Chen, P., Wu, W., Wu, H., Lan, C.-H., Huang, Y., Cheng, C., Chen, K., & Lin, C. (2017) · International Journal of Cancer · doi:10.1002/ijc.30888 · Cited by 45 · see citing works

Regulation of cancer glutamine metabolism by EphA2 RTK-dependent activation of transcriptional co-activators YAP and TAZ

Edwards, D. N., Ngwa, V. M., Wang, S., Shiuan, E., Brantley-Sieders, D. M., Kim, L. C., Reynolds, A. B., & Chen, J. (2017) · Science Signaling · doi:10.1126/scisignal.aan4667 · Cited by 44 · see citing works

CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells

Tsai, H., Huang, C., Su, H., & Tang, C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.007 · Cited by 43 · see citing works

YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma

Yang, C., Tan, J., Zhu, J., Wang, S., & Wei, G. (2017) · Oncotarget · doi:10.18632/oncotarget.16209 · Cited by 43 · see citing works

A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity

Ji, D., Deeds, S., & Weinstein, E. J. (2007) · Oncology Reports · doi:10.3892/or.18.6.1499 · Cited by 42 · see citing works

Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ)

Gandhirajan, R. K., Jain, M., Walla, B., Johnsen, M., Bartram, M. P., Anh, M. H., Rinschen, M. M., Benzing, T. R., & Schermer, B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712539 · Cited by 42 · see citing works

CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK/MEK/ERK signal pathway in colorectal cancer

Yang, K., Gao, K., Hu, G. M., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s108929 · Cited by 40 · see citing works

Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development

Pin, L., Calvisi, D. F., Kiss, A., Cigliano, A., Schaff, Z., Che, L., Ribback, S., Dombrowski, F., Zhao, D., & Chen, X. (2017) · Oncotarget · doi:10.18632/oncotarget.20622 · Cited by 38 · see citing works

Role of YAP in lung cancer resistance to cisplatin

Song, J., Xie, L., Zhang, X., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9141 · Cited by 38 · see citing works

Phase II study of gemcitabine in advanced colorectal adenocarcinoma

Moore, D. F., Pazdur, R. M., Daugherty, K., et al. (1992) · Investigational New Drugs · doi:10.1007/bf00944189 · Cited by 33 · see citing works

Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells

Liu, B., Xia, H., Zhou, S., Liu, Q., Tang, Q., Bi, N., Zhou, J., Gong, Q., Nie, Y., & Bi, F. (2018) · Oncology Reports · doi:10.3892/or.2018.6630 · Cited by 33 · see citing works

miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2

Mohamed, Z., Hassan, M. K., Okasha, S., Mitamura, T., Keshk, S., Konno, Y., Kato, T., El‐Khamisy, S. F., Ohba, Y., & Watari, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25698 · Cited by 32 · see citing works

Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells

Wang, X., Wu, B., & Zhong, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.8633 · Cited by 31 · see citing works

Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells

Lü, T., Sun, L., & Zhu, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.031 · Cited by 29 · see citing works

Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression

Guo, L., Zheng, J., Zhang, J., Wang, H., Shao, G., & Teng, L. (2016) · Oncology Reports · doi:10.3892/or.2016.4875 · Cited by 28 · see citing works

Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling

Zhao, Y., & Yang, X. (2015) · Oncotarget · doi:10.18632/oncotarget.4259 · Cited by 24 · see citing works

Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin

Lone, S. H., Bhat, K. A., Majeed, R., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.018 · Cited by 24 · see citing works

Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia

Chorzalska, A. D., Kim, J. F., Roder, K., Tepper, A., Ahsan, N., Rao, R. S. P., Olszewski, A. J., Yu, X., Terentyev, D. A., Morgan, J. W., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0262 · Cited by 22 · see citing works

Identification of Cdk1–LATS–Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells

Yeung, B., Khanal, P., Mehta, V., Trinkle‐Mulcahy, L., & Yang, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0684 · Cited by 21 · see citing works

Phase II study of amonafide in advanced pancreatic adenocarcinoma

Linke, K. A., Pazdur, R. M., Abbruzzese, J. L., et al. (1991) · Investigational New Drugs · doi:10.1007/bf00183580 · Cited by 19 · see citing works

Augmentation of the therapeutic efficacy of WEE 1 kinase inhibitor AZD 1775 by inhibiting the YAP –E2F1– DNA damage response pathway axis

Oku, Y., Nishiya, N., Tazawa, T., Kobayashi, T., Umezawa, N., Sugawara, Y., & Uehara, Y. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12440 · Cited by 19 · see citing works

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Infante, J. R., Gandi, L., Shapiro, G. I., Rizvi, N. A., Burris, H. A., Bendell, J. C., Baselga, J. M., Hsu, K., von Richter, O., Locatelli, G., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-147 · Cited by 18 · see citing works

TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma

Xu, W., Wei, Y., Li, Y., Yin, Y., Yuan, W., Yan, Y., Zhao, W., & Wu, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5847 · Cited by 15 · see citing works

The Hippo signaling pathway: an emerging anti-cancer drug target.

Tao, Y., Cai, F., Shan, L., et al. (2017) · PubMed · Cited by 13 · see citing works

Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation

Oku, Y., Nishiya, N., Sugiyama, S., Sato, H., & Uehara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.12617 · Cited by 11 · see citing works

Phase II Trial of 5-Fluorouracil/Leucovorin/Gemcitabine/Cisplatin as Second-Line Treatment in Patients with Metastatic or Recurrent Colorectal Carcinoma: A Cancer Therapeutics Research Group Study

Chang, A. Y., Lopes, G. D. L., Jr., Hsin, K. W., et al. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.033 · Cited by 8 · see citing works

A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer.

Heestand, G. M., Pipas, J. M., Valone, F. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.269 · Cited by 7 · see citing works

Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine

Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860 · see citing works

Insights into recent findings and clinical application of YAP and TAZ in cancer

Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213 · see citing works

Therapeutic targeting of TEAD transcription factors in cancer

Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147 · see citing works

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

Mukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105 · see citing works

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2994 · Cited by 91 · see citing works

Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature

Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82 · see citing works

Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling

Fan, M., Lu, W., Che, J., Kwiatkowski, N. P., Gao, Y., Seo, H.-S., Ficarro, S. B., Gokhale, P. C., Liu, Y., Geffken, E. A., et al. (2022) · eLife · doi:10.7554/elife.78810 · Cited by 68 · see citing works

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis

Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31 · see citing works

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

Tammaccaro, S. L., Prigent, P., Le Bail, J.-C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J.-C., Veeranagouda, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040553 · Cited by 18 · see citing works

ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ

Атабекова, Б. Б. (2024) · Habaršy. Pedagogika ġylymdary seriâsy · doi:10.51889/2959-5762.2023.80.4.019

Cloning and Characterization of Rat BAT3 cDNA

Ozaki, T., Hanaoka, E., Naka, M., et al. (1999) · DNA and Cell Biology · doi:10.1089/104454999315222 · Cited by 22 · see citing works

EFFECT OF THE NEMATODE PHASMARHABDITIS HERMAPHRODITA ON YOUNG STAGES OF THE PEST SLUG ARION LUSITANICUS

Grimm, B. (2002) · Journal of Molluscan Studies · doi:10.1093/mollus/68.1.25 · Cited by 41 · see citing works

HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53Preprint

Sasaki, T., Gan, E. C., Wakeham, A. C., Kornbluth, S. A., Mak, T. W., & Okada, H. (2007) · Genes & Development · doi:10.1101/gad.1534107 · Cited by 127 · see citing works

Anthoxanthum Mosaic Virus

Catherall, P. L. (1970) · Plant Pathology · doi:10.1111/j.1365-3059.1970.tb00999.x · Cited by 6 · see citing works